Sabon Magani Yana Rage ƙaiƙayi da amya daga urticaria na yau da kullun

A KYAUTA Kyauta 3 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

A cikin wannan gwaji na Mataki na 3, Dupixent ya ƙara zuwa daidaitattun magungunan antihistamines kusan ninki biyu a rage yawan ƙaiƙayi da ƙididdige ayyukan urticaria idan aka kwatanta da ma'auni na kulawa kawai a cikin makonni 24 a cikin marasa lafiya-naïve marasa kulawa akan maganin antihistamines.

Bayanai sun ƙarfafa yuwuwar yin niyya na IL-4 da IL-13, manyan direbobi na nau'in kumburin nau'in 2, a cikin wannan hadaddun cuta na yau da kullun.

Regeneron Pharmaceuticals, Inc. da Sanofi a yau sun sanar da cikakken sakamako mai kyau na Dupixent® (dupilumab) a cikin marasa lafiya tare da urticaria na yau da kullum (CSU) waɗanda ke da ilimin halitta-naïve (watau, ba a bi da su a baya tare da omalizumab). Gwajin gwaji mai mahimmanci ya nuna ƙara Dupixent zuwa daidaitattun maganin antihistamines sun rage ƙaiƙayi da amya a makonni 24 idan aka kwatanta da maganin antihistamines kaɗai a cikin wannan yanayin bincike. Za a gabatar da waɗannan sakamakon yau a cikin wani zama na ƙarshe a taron shekara-shekara na Cibiyar Allergy, Asthma da Immunology (AAAAAI) na 2022 na Amurka.

"Duk da daidaitattun maganin antihistamines, yawancin marasa lafiya da ke fama da urticaria na yau da kullum suna ci gaba da gwagwarmaya tare da matsananciyar ƙaiƙayi, ƙonawa da zafi da ke hade da amya da kumburi a ƙarƙashin fata, wanda zai iya rushe rayuwarsu ta yau da kullum," in ji Marcus Maurer, MD, Farfesa. na Dermatological Allergology, Clinic for Dermatology, Venerology da Allergology a Jami'ar Medicine na Charité a Berlin, Jamus. "Wadannan sakamako masu ƙarfafawa sun nuna cewa, a cikin waɗanda ba za su iya samun maganin cututtuka a kan maganin antihistamines kadai ba, marasa lafiya da suka kara da dupilumab sun sami ingantattun alamomi da alamun cututtuka da kuma kula da cutar su."

Sakamako mafi girma daga bazuwar, makafi biyu, gwaji mai mahimmanci mai sarrafa wuribo, wanda ya sadu da firamare da duk mahimman abubuwan ƙarshe na biyu a mako na 24, an sanar da su a cikin Yuli 2021. Bayanan da aka gabatar a taron shekara-shekara na 2022 AAAAI ya nuna cewa marasa lafiya waɗanda suka ƙara Dupixent zuwa daidaitattun daidaito. Magungunan antihistamines na kulawa sun kusan ninka sau biyu rage raguwar ƙaiƙayi da ayyukan urticaria idan aka kwatanta da daidaitattun kulawa kaɗai (placebo) tare da ci gaba da haɓakawa zuwa makonni 24. Waɗannan marasa lafiya sun sami wani:

• Rage 63% a cikin tsananin ƙaiƙayi tare da Dupixent tare da 35% tare da placebo, kamar yadda aka auna ta hanyar 0-21 ma'auni mai tsanani (raguwar maki 10.24 tare da Dupixent tare da raguwar maki 6.01 tare da placebo, p <0.001), farkon ƙarshen ƙarshe a Amurka. (Mataki na biyu a cikin EU).

• 65% ragewa a cikin aikin urticaria (itch da hive) mai tsanani tare da Dupixent tare da 37% tare da placebo, kamar yadda aka auna ta hanyar 0-42 ma'auni na urticaria (raguwa 20.53 tare da Dupixent tare da 12.00 raguwa tare da placebo, p<0.001), farkon ƙarshen EU (maki na biyu a cikin Amurka).

Gwajin ya nuna sakamakon aminci mai kama da sanannen bayanin martabar aminci na Dupixent a cikin alamun da aka amince da shi na dermatology. Don lokacin jiyya na makonni 24, gabaɗayan ƙimar abubuwan da suka faru mara kyau sun kasance iri ɗaya tsakanin ƙungiyoyin Dupixent da placebo (50% Dupixent, 59% placebo). Babban abin da ya fi dacewa shine halayen wurin allura (11% Dupixent, 13% placebo).

Yiwuwar yin amfani da Dupixent a cikin CSU a halin yanzu yana ƙarƙashin haɓakar asibiti, kuma duk wata hukuma mai ƙarfi ba ta kimanta aminci da inganci ba.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...